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OBJECTIVE
This 12-week study assessed the efficacy and tolerability of imeglimin as add-on
therapy to the dipeptidyl peptidase-4 inhibitor sitagliptin in patients with type 2
diabetes inadequately controlled with sitagliptin monotherapy.
RESEARCH DESIGN AND METHODS
In a multicenter, randomized, double-blind, placebo-controlled, parallel-group
study, imeglimin (1,500 mg b.i.d.) or placebo was added to sitagliptin (100 mg
q.d.) over 12weeks in 170 patients with type 2 diabetes (mean age 56.8 years; BMI
32.2 kg/m2) that was inadequately controlled with sitagliptin alone (A1C ‡7.5%)
during a 12-week run-in period. The primary efficacy end point was the change in
A1C from baseline versus placebo; secondary end points included corresponding
changes in fasting plasma glucose (FPG) levels, stratification by baseline A1C, and
percentage of A1C responders.
RESULTS
Imeglimin reduced A1C levels (least-squares mean difference) from baseline
(8.5%) by 0.60% compared with an increase of 0.12% with placebo (between-
group difference 0.72%, P < 0.001). The corresponding changes in FPG were
20.93 mmol/L with imeglimin vs. 20.11 mmol/L with placebo (P = 0.014). With
imeglimin, the A1C level decreased by ‡0.5% in 54.3% of subjects vs. 21.6% with
placebo (P< 0.001), and 19.8% of subjects receiving imeglimin achieved a decrease
in A1C level of £7% compared with subjects receiving placebo (1.1%) (P = 0.004).
Imeglimin was generally well tolerated, with a safety profile comparable to pla-
cebo and no related treatment-emergent adverse events.
CONCLUSIONS
Imeglimin demonstrated incremental efficacy benefits as add-on therapy to
sitagliptin, with comparable tolerability to placebo, highlighting the potential
for imeglimin to complement other oral antihyperglycemic therapies.
Numerous pharmacological agents for the treatment of type 2 diabetes are avail-
able, but many of these agents are associated with side effects and contraindica-
tions that limit their use (1,2). Furthermore, the progressive nature of the disease
will require the use of combination therapy in many patients over time to attain or
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maintain their A1C treatment goals (3).
Therefore, as type 2 diabetes remains a
challenge to control, there is a need for
new and better tolerated combination
therapies with complementary mecha-
nisms of action (4).
Imeglimin ((6R)-(+)-4-dimethylamino-
2-imino-6methyl-1,2,5,6-tetrahydro-
1,3,5, triazine hydrochloride) is the first
in a new tetrahydrotriazine-containing
class of oral antidiabetic agents, the
glimins. In preclinical studies, imeglimin
has been shown to reduce excessive
hepatic glucose production, increase
glucose uptake in skeletal muscle, and
improve insulin secretion in response
to glucose (5). Imeglimin offers a unique
mechanism of action that targets the
mitochondria and is compatible with
drugs that counter insulin resistance or
enhance insulin secretion and b-cell
protection.
Imeglimin is effective as monother-
apy in achieving glycemic control, and
has exhibited a favorable tolerability
profile in two phase IIa studies com-
pared with metformin, with no serious
adverse events reported (6). As preclin-
ical data have shown that imeglimin acts
on both insulin-resistant organs and
b-cells, the effects of imeglimin have
been investigated as an add-on to ther-
apies targeting the liver (metformin)
and b-cell (dipeptidyl peptidase-4
[DPP-4] inhibitor). In a recently pub-
lished add-on trial (7), imeglimin was
shown to improve glycemic control in
people with type 2 diabetes that was
inadequately controlled by metformin
monotherapy. The current study exam-
ined the efficacy, safety, and tolerability
of imeglimin when added to sitagliptin,
a DPP-4 inhibitor known to increase
glucose-stimulated insulin secretion
(8,9), in patients with type 2 diabetes
that was inadequately controlled with
sitagliptin therapy alone.
RESEARCH DESIGN AND METHODS
This was a 12-week,multicenter (29 cen-
ters in three countries), randomized,
double-blind, placebo-controlled, parallel-
group study in subjects with type 2 di-
abetes that was inadequately controlled
by 100 mg q.d. sitagliptin monotherapy
(Fig. 1). Because sitagliptin is usedmainly
as second-line therapy, very few individ-
uals failing sitagliptin monotherapy are
available. Therefore, after a 3-week
screening period, eligible subjects were
switched from previous treatment
(10% were treatment-naive, and 90%
were receiving other antihyperglycemic
treatments, mainlymetformin, although
some were receiving sulfonylurea and/
or a combination of agents) to 100 mg
q.d. sitagliptin for a 12-week run-in pe-
riod prior to randomization. Any subject
who had received thiazolidinediones
or insulin within 12 weeks prior to
randomization was excluded from the
study. To ensure subject compliance,
there was a single-blind placebo run-in
period 2 weeks before randomization,
in which subjects received placebo
twice daily in addition to the sitagliptin
run-in dose. Subjects were then ran-
domized 1:1 to receive 1,500 mg b.i.d.
imeglimin or placebo, while continuing
sitagliptin therapy for 12 weeks, fol-
lowed by a 1-week follow-up period
with placebo.
Male and female subjects (N = 170),
18–75 years of age, with a BMI of 20–40
kg/m2 and type 2 diabetes that was in-
adequately controlled by sitagliptin
monotherapy at randomization (A1C
$7.5%) were included in the double-
blind add-on to sitagliptin treatment pe-
riodwith imeglimin or placebo. No other
antihyperglycemic agents were allowed
to be used during the course of the
study. However, most other therapeutic
classes of concomitant medication for
comorbidities were permitted. Further
exclusion criteria included uncontrolled
hypertension and impaired hepatic or
renal function.
The study protocol was approved by
the institutional review board, and con-
ducted in accordance with the Declara-
tion of Helsinki good clinical practice
guidelines (10). All participants provided
written informed consent before any
study-related activities.
The primary efficacy outcomewas the
change in A1C level from baseline to
week 12 versus placebo. Secondary
end points included changes from base-
line versus placebo at week 12, in fasting
plasma glucose (FPG), fasting plasma in-
sulin, C-peptide concentration, ho-
meostasis model assessment-insulin
resistance (HOMA-IR), proinsulin/insu-
lin ratio, triglycerides, high-sensitivity
C-reactive protein (hs-CRP), blood pres-
sure, and proportion of subjects requir-
ing rescue therapy. Subgroup analyses
were also conducted to determine the
effect of baseline A1C level and BMI on
the change in A1C from baseline to week
12. Safety monitoring included assess-
ments of reported adverse events and
changes in vital signs and laboratory var-
iables. Body weight andwaist circumfer-
ence changes were recorded.
Statistical Analysis
All primary and secondary efficacy vari-
ables were analyzed using the intention-
to-treat (ITT) population. The primary
end point was also analyzed in the
per-protocol population to confirm the
findings in the ITT population. Change-
of-efficacy variables from baseline to
week 12 or the last observation carried
forward (LOCF) was assessed using an
ANCOVA model, with country and treat-
ment effect as factors, and baseline val-
ues as covariates. The proportion of
subjects who achieved an A1C response
at week 12 or LOCF (A1C #7%, 53
mmol/mol, or a decrease in A1C of
$0.5%) was assessed using logistic re-
gression analysis, taking into account
country and treatment, and baseline val-
ues as covariates. Safety and tolerability
were analyzed using the safety popula-
tion. All statistical tests were assessed
at the 5% level, and all quoted CIs were
two-sided 95% CIs. Unless stated other-
wise, values are expressed as least-
squares (LS) means 6 SEM.
RESULTS
Patient disposition is shown in Supple-
mentary Fig. 1. Baseline demographic
and clinical characteristics were similar
between treatment groups (Fig. 1).
A total of 170 subjects were randomized
to receive treatment. In the ITT popula-
tion, 81 subjects received 1,500mg b.i.d.
imeglimin, and 88 subjects received
placebo, in addition to their run-in
dose of 100 mg q.d. sitagliptin. There
were two discontinuations in the
imeglimin group (withdrawal by sub-
ject for personal reasons) and four dis-
continuations in the placebo group
(two withdrawals by subjects for per-
sonal reasons, and two subjects were
rescued for hyperglycemia). These last
two subjects were withdrawn from the
study in order to receive an appropri-
ate glucose-lowering medication at the
discretion of the investigator.
During the 12-week double-blind
add-on treatment period, the addition
of imeglimin to sitagliptin therapy dem-
onstrated incremental efficacy benefits
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in the primary end point, A1C level from
baseline, in all subjects (20.60%), com-
paredwith no significant change (0.12%)
with placebo. The difference in the LS
mean change from baseline versus
placebo in the ITT population was
20.72% (P , 0.001) (Fig. 2A).
Approximately 90% of subjects in
the ITT population at screening were
previously treated with metformin
monotherapy, and 10% were naive to
treatment. The mean A1C value for
the ITT population at screening was
8.5% (69 mmol/mol). After the 12-week
sitagliptin monotherapy run-in period,
the overall mean A1C value at baseline
remained at 8.5% (69 mmol/mol); how-
ever, changes in A1C level varied among
subjects. Indeed, stratification by A1C
value at screening showed that 32% of
subjects had an A1C level of ,8.0%
(,64 mmol/mol); 46% of subjects had an
A1C level ranging from 8.0 to 9.0% (64–75
mmol/mol); and 22% of subjects had an
A1C level of .9.0% (.75 mmol/mol).
After switching from their previous
therapy to sitagliptin monotherapy in
the 12-week sitagliptin run-in period,
A1C values changed by 0.67%, 0.03%,
and 20.88% in the A1C screening
groups ,8.0% (,64 mmol/mol), 8.0–
9.0% (64–75 mmol/mol), and .9.0%
(.75 mmol/mol), respectively.
After the 12-week double-blind treat-
ment period, imeglimin therapy was
shown to be more effective than pla-
cebo in reducing A1C levels from base-
line to week 12 for all prespecified
baseline A1C subgroup measurements.
Placebo-subtracted reductions in mean
A1C level from baseline to week 12 with
imeglimin were 20.78%, 20.62%, and
20.95% for A1C baseline subgroups
,8.0% (,64 mmol/mol), 8.0–9.0%
(64–75 mmol/mol), and .9.0% (.75
mmol/mol), respectively (Fig. 2B).
There was a statistically significant
difference in the proportion of subjects
(19.8%) achieving an A1C level of #7%
(53 mmol/mol), and the proportion of
those (54.3%) experiencing a decrease
Figure 1—Imeglimin add-on to sitagliptin study design.
Figure 2—A: Effect of sitagliptin-imeglimin vs. sitagliptin-placebo: A1C reductions over the 12-
week double-blind treatment period. B: Effect of sitagliptin-imeglimin vs. sitagliptin-placebo:
change in A1C depending on baseline A1C value.
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in A1C of at least 0.5% with imeglimin
versus placebo (1.1% [P = 0.004] and
21.6% [P , 0.001], respectively).
Reductions in A1C levels from base-
line were similar for imeglimin treat-
ment when subjects were stratified by
baseline BMI #30 kg/m2 (20.66%) and
.30 kg/m2 (20.62%). No reduction in
A1C was observed with placebo treat-
ment for either BMI baseline subgroup.
Imeglimin treatment also decreased
mean FPG levels from baseline after 12
weeks by 20.93 mmol/L, and by 20.11
mmol/L in the placebo group, resulting
in an LS mean treatment difference of
20.81 mmol/L (95% CI21.46 to20.17,
P , 0.014).
There were no significant differences
in the mean changes from baseline to
week 12 between treatment groups for
parameters ofb-cell function (fasting in-
sulin concentration, C-peptide concen-
tration, HOMA-IR, proinsulin/insulin
ratio) and for other parameters (triglyc-
eride and hs-CRP levels, and systolic
blood pressure) (Table 1).
Imeglimin as an add-on to sitagliptin
therapy was generally well-tolerated
during the double-blind run-in period
(Table 2). A higher incidence of
treatment-emergent adverse events
(TEAEs) considered to be related to
study medication was reported during
the double-blind treatment period in
the placebo group (seven events in
three subjects), compared with the im-
eglimin group, in which no related TEAEs
were reported. One subject in the pla-
cebo group required rescue therapy,
whereas none was necessary in the
imeglimin group. One subject in the
imeglimin group experienced a serious
adverse event not related to treatment
during the double-blind treatment pe-
riod (surgery for appendicitis).
CONCLUSIONS
The current study demonstrates that
imeglimin 1,500 mg b.i.d. added to on-
going sitagliptin therapy for 12 weeks is
well-tolerated and demonstrates incre-
mental efficacy benefits in reducing lev-
els of A1C versus placebo in patients
with type 2 diabetes that was inade-
quately controlled with sitagliptin
alone.
In order to investigate the effect of
imeglimin when added to sitagliptin
monotherapy, the study was designed
to treat a study population with type 2
diabetes that was inadequately con-
trolled with sitagliptin monotherapy.
The A1C value of 8.5% (69 mmol/mol)
at screening demonstrates that subjects
with type 2 diabetes that was inade-
quately controlled with their current
treatment regimen (subjects were pre-
dominately receiving metformin) and
were therefore switched to sitagliptin
monotherapy. In this 12-week period,
and after a switch from their previous
monotherapy to sitagliptin, 25% of sub-
jects demonstrated improvements in
A1C level; 25% of subjects saw their
A1C levels deteriorate and levels in
50% of subjects remained stable. How-
ever, for the entire study population,
the baseline A1C value remained un-
changed at the end of this run-in period
compared with the A1C value at screen-
ing (8.5% [69 mmol/mol]). Only those
subjects with type 2 diabetes that re-
mained uncontrolled (A1C level $7.5%
[58 mmol/mol]) were randomized to re-
ceive imeglimin or placebo.
Although sitagliptin has been exten-
sively studied, both as a monotherapy
and in combination with other antihy-
perglycemic treatments (11–14), the
current study represents an original de-
sign intended to investigate the incre-
mental efficacy benefits in patients
with type 2 diabetes that was subopti-
mally controlled with sitagliptin mono-
therapy. One study (15) implementing
a similar design demonstrated that the
sodium-glucose cotransporter 2 inhibitor
dapagliflozin, when added to sitagliptin
therapy, reduced A1C level by 20.56%
versus placebo, similar to the 20.72%
difference achieved in our study. More-
over, since the mean A1C value in the
sitagliptin-imeglimin treatment group
was not yet plateauing, further incre-
mental effects on improvements in
A1C level beyond 12 weeks might be
anticipated; this will be investigated in
an ongoing 24-week phase IIb dose-
ranging study.
The current study also demonstrates
that, regardless of baseline A1C level, a
greater and significant reduction in A1C
level was observed in the group receiv-
ing treatment with imeglimin compare
with placebo, even for those patients
with a baseline A1C level of ,8.0% (64
mmol/mol). Although the full effect of
DPP-4 inhibitors can be obtained in
10–12 weeks, a varying A1C response
was observed across different subgroups
receiving placebo in the double-blind
treatment period (0.31%, 20.05%, and
0.16% for baseline A1C values of ,8.0%
[64 mmol/mol], 8.0–9.0% [64–75
mmol/mol], and .9.0% [75 mmol/mol],
respectively). This may be attributed to
baseline values being recorded at the
end of the run-in period, with individual
subject factors, such as previous metfor-
min dose and treatment compliance,
influencing A1C level during the double-
blind treatment period.
The study also examined the effect on
A1C values during the sitagliptin run-in
period. For the subgroup of subjects ex-
hibiting an A1C level of .9.0% (75
mmol/mol) at screening, the switch
from previous treatment to sitagliptin
for 12 weeks resulted in a decrease in
A1C of 0.87%, with the addition of
imeglimin for a further 12 weeks con-
tributing to an incremental decrease in
A1C of 0.74%, resulting in a total A1C
reduction of 1.61% over the 24-week
treatment period. Considering that in
this subpopulation the A1C value at
screening was 8.5% (69 mmol/mol)
and remained stable during the run-
in period with sitagliptin, this current
study demonstrates the potential of
imeglimin to complement the efficacy
of DPP-4 inhibitors.
No statistically significant effects on
fasting insulin concentration, C-peptide
concentration, or HOMA-IR were ob-
served with sitagliptin-imeglimin treat-
ment compared with sitagliptin-placebo
as demonstrated by the insulin/glucose
and C-peptide/glucose ratios. The
glucose-lowering effects of imeglimin in
combination with sitagliptin demon-
strated in the current study, and the pre-
vious observations in combination with
metformin (7), suggest that the mecha-
nism of action of imeglimin is comple-
mentary to and therefore additive to
both DPP-4 inhibition and metformin ac-
tion. Additional mechanistic studies will
be necessary to confirm the precise con-
tributions of imeglimin to correcting
some of the many pathophysiological
defects encountered in patients with
type 2 diabetes.
Imeglimin add-on to sitagliptin ap-
peared to be well tolerated, with no se-
rious treatment-related adverse events
reported. The greater incidence of ad-
verse events in the placebo group com-
pared with the imeglimin group during
the double-blind treatment period
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could be indicative that type 2 diabetes
in the subjects receiving placebo was in-
adequately controlled with sitagliptin
monotherapy, as demonstrated by the
higher number of subjects presenting
with hyperglycemia or having their A1C
elevation noticed as adverse events
(with two subjects receiving rescue
therapy). The absence of reported hypo-
glycemia in the imeglimin add-on to
sitagliptin treatment group is notewor-
thy, given the significant glucose-lowering
effects observed in subjects receiving this
combination.
Positive trends for improvements in
triglyceride and hs-CRP levels, and
systolic blood pressure were observed
in the group of patients receiving
imeglimin treatment compared with
the group receiving placebo. In combi-
nation with sitagliptin, imeglimin treat-
ment had a neutral effect on body
weight and waist circumference, which
contrasts with previous studies where
Table 1—Efficacy end points, week 12 (LOCF) (ITT population)
Efficacy end point
Sitagliptin + imeglimin




Baseline 8.47 [69] (0.72) 8.53 [70] (0.66)
Week 12/end of treatment 7.83 [62] (0.9) 8.61 [71] (0.95)
Change from baseline to week 12 (LOCF)* 20.6 (0.11) 0.12 (0.10)
P value compared with placebo ,0.001
FPG (mmol/L) 10.91 (2.31)
Baseline 10.53 (2.09)
Week 12/end of treatment 9.74 (2.39) 10.69 (2.07)
Change from baseline to week 12 (LOCF)* 20.93 (0.31) 20.11 (0.29)
P value compared with placebo 0.014
Insulin (mIU/mL)
Baseline 9.31 (8.24) 12.5 (32.01)
Week 12/end of treatment 8.95 (7.34) 10.58 (14.36)
Change from baseline to week 12 (LOCF)* 21.17 (0.78) 20.81 (0.72)
P value compared with placebo 0.655
C-peptide (ng/mL)
Baseline 3.48 (1.43) 3.32 (1.54)
Week 12/end of treatment 3.58 (1.56) 3.47 (1.67)
Change from baseline to week 12 (LOCF)* 0.17 (0.13) 0.23 (0.12)
P value compared with placebo 0.663
Proinsulin/insulin ratio
Baseline 534.69 (305.21) 642.52 (553.34)
Week 12/end of treatment 462.6 (308.22) 557.58 (527.8)
Change from baseline to week 12 (LOCF)* 2120.51 (46.98) 280.98 (43.93)
P value compared with placebo 0.428
HOMA-IR
Baseline 5.14 (4.8) 5.22 (4.98)
Week 12/end of treatment 4.46 (3.59) 5.52 (7.02)
Change from baseline to week 12 (LOCF)* 20.184 (0.68) 0.098 (0.64)
P value compared with placebo 0.572
Triglycerides (mmol/L)
Baseline 2.35 (1.36) 2.36 (1.45)
Week 12/end of treatment 2.26 (1.50) 2.55 (2.17)
Change from baseline to week 12 (LOCF)* 20.167 (0.19) 0.161 (0.18)
P value compared with placebo 0.106
hs-CRP (mg/L)
Baseline 4.04 (5.58) 4.64 (4.87)
Week 12/end of treatment 3.42 (4.94) 4.75 (4.82)
Change from baseline to week 12 (LOCF)* 21.16 (0.64) 0.009 (0.59)
P value compared with placebo 0.082
Systolic blood pressure (mmHg)
Baseline 132.0 (10.2) 132.8 (10.3)
Week 12/end of treatment 132.8 (10.3) 135.9 (9.2)
Change from baseline to week 12 (LOCF)* 1.0 2.8
Change compared with placebo 21.8
Diastolic blood pressure (mmHg)
Baseline 79.3 (7.1) 80.7 (6.6)
Week 12/end of treatment 80.2 (6.8) 81.3 (7.2)
Change from baseline to week 12 (LOCF)* 0.9 0.6
Change compared with placebo 0.3
Data are the mean (SD), unless otherwise stated. *Data are the LS mean (SE) or mean difference.
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imeglimin reduced these parameters
(6,7). Longer-term studies that include
body weight measurements will clarify
these effects.
In summary, this original study design
demonstrates that the addition of
imeglimin to sitagliptin monotherapy
provides incremental efficacy benefits
in reducing A1C and FPG levels in sub-
jects with type 2 diabetes that was in-
adequately controlled with sitagliptin
monotherapy, particularly in subjects
with a high baseline A1C level (.9.0%
[75 mmol/mol]) at screening. The cur-
rent data, along with previous studies
(6,7), have shown imeglimin to be a
well-tolerated and effective treatment,
both as monotherapy and in combina-
tion with other antihyperglycemic
agents, and therefore may provide a
valuable new treatment option for pa-
tients with type 2 diabetes. Further
longer-duration studies in the phase
IIb/III programwill help to confirm these
primary results.
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Constipation 1 (1.2) 1 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
Vomiting 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (1.1) 2
Investigations 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (1.1) 1
Weight increased 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (1.1) 1
Metabolism 1 (1.2) 4 0 (0.0) 0 0 (0.0) 0 2 (2.3) 2
Hyperglycemia 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (1.1) 1
Hypoglycemia 1 (1.2) 4 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
Increased appetite 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (1.1) 1
CNS 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (1.1) 1
Headache 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (1.1) 1
Any SAE 0 (0.0) 0 1 (1.2) 1 0 (0.0) 0 0 (0.0) 0
Any cardiovascular TEAE 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
E, number of events; N, number of subjects exposed; n, number of subjects with adverse events; SAE, serious adverse event.
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